# Cullinan Therapeutics, Inc.: overview CGEM · Nasdaq · CIK 1789972 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cgem.md) · [Financials](/companies/cgem/financials.md) · [Filings](/companies/cgem/filings.md) · [Insiders](/companies/cgem/insiders.md) Latest reported revenue: [$0](/filings/0000950170-23-006839.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 9, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-23-006839). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.69)](/filings/0000950170-24-122795.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(34.1) d](/filings/0001193125-25-268066.md) | [(36.6) d](/filings/0001193125-26-099362.md) | not reported | not reported | not reported | [(38.1) d](/filings/0001193125-26-099362.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.9](/filings/0000950170-23-006839.md) | [0.0](/filings/0000950170-23-006839.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(358.7%)](/filings/0000950170-23-006839.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(346.1%)](/filings/0000950170-23-006839.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.52)](/filings/0000950170-23-006839.md) | [2.38](/filings/0000950170-24-031143.md) | [(3.69)](/filings/0000950170-24-031143.md) | not reported | not reported | | Free cash flow | $m | [(43.4)](/filings/0000950170-23-006839.md) | [(128)](/filings/0000950170-24-031143.md) | [(134)](/filings/0000950170-25-028346.md) | [(145)](/filings/0001193125-26-099362.md) | [(176)](/filings/0001193125-26-099362.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cgem/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $177.2m | 9,731,341 | | Added +2,083,073 | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $163.2m | 8,963,500 | | Unchanged | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $104.7m | 5,750,683 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $95.3m | 5,232,766 | | Added +782,800 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $66.8m | 3,668,627 | | Added +1,124,512 | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $56.7m | 3,114,132 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $47.6m | 2,614,066 | | Added +131,032 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $43.1m | 2,364,347 | | Added +658,387 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $34.5m | 1,893,410 | | Added +700,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $28.2m | 1,547,309 | | Added +179,041 | ## Recent filings [All 459 filings](/companies/cgem/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 23:35 ET | [8-K](/filings/0001193125-26-411011.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-411011 | | 2026-09-24 | 11:15 ET | [8-K](/filings/0001193125-26-400144.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-400144 | | 2026-09-14 | 11:29 ET | [8-K](/filings/0001193125-26-389844.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389844 | | 2026-08-13 | 23:35 ET | [8-K](/filings/0001193125-26-347400.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-347400 | | 2026-08-06 | 11:10 ET | [10-Q](/filings/0001193125-26-336717.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336717 | | 2026-08-06 | 11:06 ET | [8-K](/filings/0001193125-26-336700.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336700 | | 2026-06-16 | 21:18 ET | [8-K](/filings/0001193125-26-272890.md) | 5.07 Shareholder vote results | 0001193125-26-272890 | | 2026-06-10 | 11:32 ET | [8-K](/filings/0001193125-26-264916.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-264916 | | 2026-06-08 | 10:32 ET | [8-K](/filings/0001193125-26-260640.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-260640 | | 2026-05-18 | 21:30 ET | [8-K](/filings/0001193125-26-229173.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229173 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-099362.md), filed Mar 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1789972 - Tickers: CGEM - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.